These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32294924)

  • 21. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
    Liu B; Chen W; Li H; Li F; Jin X; Li Q
    Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
    Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J
    Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
    Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
    Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells.
    Ro EJ; Ryu SH; Park EY; Ryu JW; Byun SJ; Heo SH; Kim KH; Baek IJ; Son BH; Lee SW
    Breast Cancer Res Treat; 2020 Aug; 182(3):591-600. PubMed ID: 32529408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin.
    Zhu H; Rao Z; Yuan S; You J; Hong C; He Q; Yang B; Du C; Cao J
    Eur J Pharmacol; 2021 Oct; 908():174366. PubMed ID: 34314706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Liu Y; Burness ML; Martin-Trevino R; Guy J; Bai S; Harouaka R; Brooks MD; Shang L; Fox A; Luther TK; Davis A; Baker TL; Colacino J; Clouthier SG; Shao ZM; Wicha MS; Liu S
    Clin Cancer Res; 2017 Jan; 23(2):514-522. PubMed ID: 28034904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of CDC20 Increases Radiosensitivity through Mcl-1/p-Chk1-Mediated DNA Damage and Apoptosis in Tumor Cells.
    Gao Y; Wen P; Chen B; Hu G; Wu L; Xu A; Zhao G
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
    Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
    Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RPA1 downregulation enhances nasopharyngeal cancer radiosensitivity via blocking RAD51 to the DNA damage site.
    Zhang Z; Huo H; Liao K; Wang Z; Gong Z; Li Y; Liu C; Hu G
    Exp Cell Res; 2018 Oct; 371(2):330-341. PubMed ID: 30144445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation.
    Zou M; Li Y; Xia S; Chu Q; Xiao X; Qiu H; Chen Y; Zheng Z; Liu F; Zhuang L; Yu S
    Cell Physiol Biochem; 2017; 44(2):778-791. PubMed ID: 29169152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer.
    Wu Z; Zhu L; Mai J; Shen H; Xu R
    J Biomed Nanotechnol; 2021 Dec; 17(12):2351-2363. PubMed ID: 34974858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.
    Wiegmans AP; Miranda M; Wen SW; Al-Ejeh F; Möller A
    Oncotarget; 2016 Sep; 7(37):60087-60100. PubMed ID: 27507046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
    Zong B; Sun L; Peng Y; Wang Y; Yu Y; Lei J; Zhang Y; Guo S; Li K; Liu S
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
    Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sterigmatocystin-induced checkpoint adaptation depends on Chk1 in immortalized human gastric epithelial cells in vitro.
    Jiang X; Wang J; Xing L; Shen H; Lian W; Yi L; Zhang D; Yang H; Liu J; Zhang X
    Arch Toxicol; 2017 Jan; 91(1):259-270. PubMed ID: 26914363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.